Tasimelteon: Phase III started

Vanda began the double-blind, placebo-controlled, U.S. Phase III trial (Study 3201) to evaluate 20 mg tasimelteon given daily for 6 months in about 160 totally blind patients. Vanda licensed tasimelte...